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Abstract
MAFB is a transcription factor involved in the terminal differentiation of several cell types, including macrophages and 
keratinocytes. MAFB is also expressed in lymphatic endothelial cells (LECs) and is upregulated by VEGF-C/VEGFR-3 
signaling. Recent studies have revealed that MAFB regulates several genes involved in lymphatic differentiation and that 
global Mafb knockout mice show defects in patterning of lymphatic vessels during embryogenesis. However, it has remained 
unknown whether this effect is LEC-intrinsic and whether MAFB might also be involved in postnatal lymphangiogenesis. We 
established conditional, lymphatic-specific Mafb knockout mice and found comparable lymphatic patterning defects during 
embryogenesis as in the global MAFB knockout. Lymphatic MAFB deficiency resulted in increased lymphatic branching 
in the diaphragm at P7, but had no major effect on lymphatic patterning or function in healthy adult mice. By contrast, 
tumor-induced lymphangiogenesis was enhanced in mice lacking lymphatic MAFB. Together, these data reveal that LEC-
expressed MAFB is involved in lymphatic vascular morphogenesis during embryonic and postnatal development as well 
as in pathological conditions. Therefore, MAFB could represent a target for therapeutic modulation of lymphangiogenesis.
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Introduction
V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
B (Mafb) belongs to the Maf family of basic leucine zip-
per transcription factors (TFs) which comprises the “large” 
Mafs (c-Maf, Mafa, Mafb, and Nrl) and the “small” Mafs 
(Maff, Mafg, and Mafk) that are characterized by the pres-
ence or absence of a transactivation domain, and thus act as 
transcriptional activators or repressors [1]. Mafb forms both 
homodimers and heterodimers with other basic leucine zip-
per TFs, including other Mafs, c-Fos, and c-Jun [2] and regu-
lates gene expression by directly binding to Maf recognition 
elements (MARE) in promoter and enhancer elements. It is 
expressed in multiple tissues and has been linked to the dif-
ferentiation of diverse cell types, including macrophages [3], 
keratinocytes [4, 5], kidney podocytes [6], and pancreatic 
α-cells and β-cells [7, 8].
Recently, we and others have found that MAFB also 
plays an important role in the embryonic development of 
the lymphatic vascular system [9, 10]. In mice, this pro-
cess is initiated at embryonic day (E) 9.5, when lymphatic 
endothelial cell (LEC) progenitors transdifferentiate from 
venous endothelial cells in the cardinal vein, acquiring 
expression of the LEC “master regulator” TF Prox1 [11] 
via coordinated activity of two other TFs, SOX18 and 
NR2F2 [12, 13]. Prox1-expressing endothelial cells bud 
off the vein between E10.5 and E11.5 and migrate into the 
periphery to establish the primordial lymph sacs, which 
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subsequently give rise to a primitive lymphatic plexus 
that further differentiates into the mature lymphatic sys-
tem comprising lymphatic capillaries, collectors, and sec-
ondary lymphoid organs (reviewed in [14]). In addition, a 
non-venous origin of a subset of dermal, mesenteric, and 
cardiac LECs has been described [15, 16].
Signaling by vascular endothelial growth factor (VEGF) 
C/VEGF receptor (VEGFR) 3 is essential for lymphatic 
development as it controls the budding/migration process 
of LEC progenitors [17] from the vein, but also maintains 
the differentiated LEC phenotype [18]. However, the precise 
transcriptional events downstream of VEGFR-3 activation 
are still not fully understood. We have recently identified 
TFs activated by VEGFR-3 signaling in LECs [10, 19, 20] 
and found that MAFB is rapidly but transiently induced 
upon receptor stimulation and that it regulates expression 
of several important LEC differentiation and marker genes, 
including Prox1, Klf4, Flt4 (VEGFR-3), LYVE-1, and 
podoplanin [10]. Furthermore, we found that global Mafb 
deficiency resulted in abnormal patterning of developing 
lymphatic vessels in the back skin of mice at embryonic day 
E14.5, characterized by hyper-branching without an obvious 
decrease in overall lymphatic vessel growth [10]. Similarly, 
Koltowska et al. showed that the homologue gene mafba is 
important for normal lymphatic development in zebrafish 
and that its expression in LECs depends upon SOX18 and 
VEGF-C stimulation [9].
Since Mafb is highly expressed in various cell types 
in the developing mouse, including macrophages that are 
important regulators of lymphatic development [21], it has 
remained unclear whether the lymphatic phenotype observed 
during embryonic lymphatic development in global Mafb 
knockout mice was due to LEC-intrinsic effects or to indirect 
effects via macrophages. Furthermore, global Mafb knock-
out mice die perinatally due to a breathing defect [22], thus 
prohibiting studies of the postnatal function of MAFB in 
lymphangiogenesis. Lymphatic development does not stop 
at birth, but continues throughout the growth phase of the 
organism. For example, the lymphatic network in the mouse 
diaphragm continues to expand and remodel at least until 
postnatal day (P) 7 [23]. Additionally, de novo lymphangi-
ogenesis can be induced in adult mice in pathological con-
ditions, such as inflammation [24] and tumor growth [25, 
26]. Lymphangiogenesis appears to play a beneficial role in 
acute and chronic inflammatory conditions, reducing edema 
and supporting the re-establishment of tissue homeostasis 
[27–29], whereas in many tumor types, lymphangiogenesis 
correlates with lymphatic metastasis and a poor outcome 
[25, 26]. Thus, a better understanding of how pathological 
lymphangiogenesis is regulated may open up new opportuni-
ties for therapeutic modulation of this process.
Here, we used both in vitro and in vivo approaches to 
investigate the LEC-intrinsic function of MAFB during 
embryogenesis, postnatal development, and pathological 
lymphangiogenesis.
Results
LEC‑expressed MAFB regulates tubular 
morphogenesis in vitro
We previously reported that global deletion of MAFB in 
mice resulted in a hyper-branching phenotype of the devel-
oping dermal lymphatic vasculature at E14.5, character-
ized by an increase in junction points, whereas the overall 
vessel length was not affected [10]. In order to determine 
whether lymphatic branching is controlled by MAFB intrin-
sically expressed by LECs, we employed an in vitro cord-
like structure assay with human dermal LECs transduced 
with an adenoviral vector to suppress MAFB expression 
(AdShMAFB) or a corresponding non-targeting control 
shRNA vector (AdNT) (Fig. S1a). In agreement with our 
previous in vivo data, MAFB depletion in LECs increased 
the number of junctions and, correspondingly, of cord seg-
ments in this assay (Fig. 1a–c). As the average length per 
segment was only slightly diminished, this resulted in an 
increase in the overall length of cord-like structures (Fig. 
S1b, c). Conversely, overexpression of MAFB in cultured 
LECs (AdMAFB) (Fig. S1d) significantly decreased the 
number of junctions and tubular segments (Fig. 1d–f). In this 
case, the average length per segment significantly increased, 
resulting in an equal overall length of cord-like structures 
between AdMAFB and AdGFP-transduced cells (Fig. S1e, 
f). Of note, neither MAFB knockdown nor overexpression 
significantly affected proliferation of cultured LECs, indicat-
ing that effects on branching were not simply due to changes 
in cell number (Fig. S1g, h). Furthermore, untransduced 
LECs downregulated MAFB expression upon initiation 
of cord-like structure formation, compared to cells grown 
as a monolayer (Fig. 1g). Together, these data suggest that 
MAFB is a LEC-intrinsic negative regulator of lymphatic 
branching.
Lymphatic MAFB intrinsically controls lymphatic 
branching during embryonic development
Next, we sought to determine whether LEC-expressed 
MAFB is indeed responsible for the lymphatic hyper-
branching phenotype during embryonic development that we 
observed previously in global knockout mice [10]. To this 
end, we generated a conditional, tissue-specific Mafb knock-
out mouse model by crossing mice with a floxed Mafb locus 
 (Mafbfl/fl) [30] with Prox1-CreERT2 mice [31], resulting in 
Mafb deletion in Prox1-expressing cells upon treatment 
with tamoxifen. To evaluate the efficiency of this model, we 
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treated newborn or adult Prox1-CreERT2 × Mafbfl/fl mice 
with tamoxifen for three or five consecutive days, respec-
tively, and eight or three weeks later, we isolated LECs and 
blood vessel endothelial cells (BECs) from the ears by FACS 
sorting (Fig. S2a, b). DNA isolation followed by genomic 
qPCR using three distinct primer pairs to detect the presence 
of the Mafb coding sequence demonstrated that the gene 
was efficiently disrupted in LECs, whereas no recombina-
tion occurred in BECs or in Cre-negative  Mafbfl/fl littermate 
controls, using either of the tamoxifen treatment regimens 
(Fig. S2c–f).
Next, we used this mouse line to investigate lymphatic 
development during embryogenesis. Tamoxifen was 
applied to pregnant females at E11.5, a timepoint at which 
lymphatic endothelial progenitor cells express Prox1 [11], 
and lymphatic branching was analyzed in the embryonic 
back skin at E14.5 (Fig. 2a).  Mafbfl/fl littermates served 
as controls. As expected, MAFB protein was detectable 
in dermal lymphatic vessels in  Mafbfl/fl embryos, but not 
in Prox1-CreERT2 × Mafbfl/fl littermates (Fig S3a). In 
agreement with our previous findings, we found a sig-
nificant increase in the number of lymphatic vessel junc-
tions and the number of lymphatic vascular segments 
(Fig. 2b, c), whereas the average segment length decreased 
(Fig. 2c). No major effects on the number of filopodia in 
the tip region of sprouting lymphatic vessels (Fig. S3b, 
c), on lymphatic vessel area (Fig. S3d) nor on the aver-
age size of the LECs (Fig S3e) were observed. Similar 
to what we reported for global Mafb knockout embryos, 
depletion of lymphatic MAFB did not alter endomu-
cin (EMCN) + blood vessels (Figs. 2b, S3f). Together, 
these data clearly demonstrate that the deletion of LEC-
expressed MAFB is sufficient to induce hyper-branching in 
the developing lymphatic system, whereas it has no major 
effect on the overall growth of lymphatic vessels in the 
embryonic skin.
Fig. 1  MAFB controls tubular morphogenesis of cultured LECs. a 
Representative images of cord morphogenesis of LECs transduced 
with an adenoviral vector to downregulate MAFB (AdShMAFB) and 
a control vector (AdNT). Quantification of the number of junctions 
(b) and cord segments (c). d Representative images of cord morpho-
genesis by LECs transduced with a MAFB overexpression vector 
(AdMAFB) in comparison to a control vector (AdGFP). Quantifica-
tion of junctions (e) and segments (f). g LECs were seeded and left 
untreated or subjected to cord morphogenesis. After 16 h, cells were 
lysed and MAFB expression was quantified by qPCR and expressed 
as fold change compared to untreated cells (steady state). Scale bars: 
100 μm. Data represent mean ± SD. Significance was determined by 
unpaired Student’s t-test (n ≥ 3 replicates/group, representative results 
of 3 independent experiments), *p < 0.05; **p < 0.01
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Lymphatic‑expressed MAFB regulates lymphatic 
branching in the diaphragm during postnatal 
development
The lymphatic system in the diaphragm undergoes extensive 
growth and remodeling in the first days after birth, repre-
senting a robust and quantifiable system to study postnatal 
lymphatic development [23]. Thus, we treated Prox1-Cre-
ERT2 × Mafbfl/fl mice and control  Mafbfl/fl littermates with 
tamoxifen from postnatal day P1 to P3 [32], and analyzed 
the lymphatic network in the diaphragm at P7 (Fig. 3a). 
We observed lymphatic hyper-branching, accompanied by 
an increase in the number of lymphatic vessel segments 
and a reduction in the average segment length (Fig. 3b, 
c), while, as in the embryonic back skin, the ratio between 
Prox1+ LEC nuclei and the lymphatic vascular area was not 
affected (data not shown). In contrast, we found that neither 
the development of the mesenteric lymphatic vasculature 
nor of the lymphatic lacteals in the jejunum was affected 
in newborn mice lacking lymphatic MAFB (Figs. S4, S5). 
Fig. 2  Lymphatic hyper-branching during embryogenesis in E14.5 
Prox1-CreERT2 ×  Mafbfl/fl embryos. a Schematic of the tamoxifen 
treatment in pregnant females and analysis of embryos. b Repre-
sentative confocal images (maximum-intensity projections) of E14.5 
embryonic back skin stained for NRP2 (green), PROX1 (red), and 
endomucin (EMCN) (blue). Arrowheads point to vessel junctions 
(branch points) within the distal sprouting area. c Number of vessel 
junctions and segments normalized to total vessel length and average 
segment length in the distal sprouting area of  Mafbfl/fl (Cre  −) and 
Prox1-CreERT2 ×  Mafbfl/fl (Cre +) littermates (n = 7 animals/group). 
Scale bars: 100  μm. Data represent mean ± SD. Significance was 
determined by unpaired Student’s t-test, *p < 0.05; **p < 0.01
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Fig. 3  Lymphatic hyper-branching in Prox1-CreERT2 ×  Mafbfl/fl 
mice during postnatal development. a Schematic representation of the 
tamoxifen treatment schedule and analysis in newborn mice. b Repre-
sentative confocal images (maximum-intensity projections) of P7 dia-
phragms stained for PROX1 (green) and LYVE-1 (red). c Number of 
vessel junctions and segments normalized to total vessel length and 
average segment length in the diaphragm (pleural side) of  Mafbfl/fl 
(Cre −) and Prox1-CreERT2 ×  Mafbfl/fl (Cre +) littermates (n = 7 ani-
mals/group). d Schematic representation of the tamoxifen treatment 
schedule and analysis in adolescent mice. e Representative confocal 
images (maximum-intensity projections) of P39 diaphragms stained 
for PROX1 (green), CD31 (red), and LYVE-1 (blue). f Number of 
vessel junctions and segments normalized to total vessel length and 
average segment length in the diaphragm (pleural side) of  Mafbfl/fl 
(Cre −) and Prox1-CreERT2 ×  Mafbfl/fl (Cre +) littermates (n = 6 ani-
mals/group). Scale bars: 100 μm. Data represent mean ± SD. Signifi-
cance was determined by unpaired Student’s t-test, *p < 0.05
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Thus, lymphatic MAFB does not affect lymphatic collectors 
in the mesentery or jejunal lacteals which never branch, but 
restrains branching of capillary lymphatic vessels during 
active developmental lymphangiogenesis.
Lymphatic MAFB is dispensable for lymphatic 
patterning and function in healthy adult mice
Since deletion of lymphatic MAFB resulted in an altered 
lymphatic patterning and hyper-branching during develop-
ment, we wondered whether these defects would translate 
into structural or functional impairments in adult mice. 
To investigate this question, we treated newborn Prox1-
CreERT2 × Mafbfl/fl mice and control  Mafbfl/fl littermates 
with tamoxifen from P1 to P3, and analyzed the lymphatic 
morphology in the diaphragm once the mice reached ado-
lescence (Fig. 3d). Interestingly, the hyper-branching pheno-
type seen in newborn pups was completely rescued in ado-
lescent mice (Fig. 3e, f). Similarly, no major changes in the 
lymphatic density or branching were observed in the ear skin 
of 8 weeks old mice (Fig. 4a–f). Overall, our results indicate 
that defects induced by a lack of MAFB in developing lym-
phatic networks are only transient and can be compensated 
during final maturation.
As a major function of the lymphatic system is to provide 
fluid drainage of peripheral tissues, we also assessed the 
transport capacity of dermal lymphatics in adult Prox1-Cre-
ERT2 × Mafbfl/fl mice and control  Mafbfl/fl littermates treated 
with tamoxifen. To do so, we injected a near-infrared lym-
phatic tracer (PEG20-IRDye800) into the ear dermis [33], 
and monitored its fluorescence decay (corresponding to the 
lymphatic clearance of the tracer) over time. In agreement 
with the overall normal lymphatic morphology, no differ-
ence in tracer clearance was detected between Prox1-Cre-
ERT2 × Mafbfl/fl mice and control  Mafbfl/fl mice (Fig. 4g, 
h), indicating that MAFB is dispensable for the lymphatic 
structure and function in healthy adult mouse skin.
Lymphatic MAFB restricts pathological 
lymphangiogenesis in adult mice
The function of lymphatic MAFB in regulating vessel 
branching might also be apparent during other phases of 
active lymphangiogenesis. Since the lymphatic network is 
largely stable and does not undergo major remodeling in 
healthy adults, we decided to pathologically trigger neo-lym-
phangiogenesis in adult Prox1-CreERT2 × Mafbfl/fl mice and 
control  Mafbfl/fl littermates. We applied tamoxifen to young 
adults (6–7 weeks old) for five consecutive days. Then, we 
used a well-established oxazolone sensitization and chal-
lenge protocol (Fig. 5a) to elicit a cutaneous hypersensitivity 
response in the ear skin which is accompanied by extensive 
lymphatic remodeling [27, 28, 34]. Deletion of lymphatic 
MAFB did not affect ear inflammation (Fig. S6a) and also 
had no major effect on the number of lymphatic vessels in 
the inflamed ears. While there was a slight increase in the 
number of lymphatic vessel profiles in tissue sections of 
Prox1-CreERT2 × Mafbfl/fl mice stained for LYVE-1 (Fig. 5b, 
c), the LYVE-1+ area and average lymphatic vessel size 
were identical (Figs. 5d and S6b). Tissue wholemount stain-
ings furthermore showed largely comparable lymphatic ves-
sel morphology and branching (Fig. S6c–f). The number and 
area of blood vessels was not affected either (Figs. 5e and 
S6g), nor was the lymphatic drainage function (Fig. S6h, i).
A setting in which pathological lymphangiogenesis and 
remodeling is more strongly induced is during tumor growth 
[25, 26]. Thus, we subcutaneously implanted BL/6 synge-
neic MC38 colorectal carcinoma cells which express high 
levels of VEGF-C [35], allowed the tumors to develop for 
17 days, and then assessed lymphatic vessels within the 
tumors histologically (Fig. 5f). Deletion of lymphatic MAFB 
increased the number of intra-tumoral lymphatic vessels 
(Fig. 5g, h), but had no significant effect on the overall area 
covered by lymphatic vessels (Fig. 5i), nor on the formation 
of tumor-associated blood vessels (Fig. 5j). The absence of 
MAFB from lymphatic vessels did not change the weight of 
tumor-draining lymph nodes (Fig. S6j) or the abundance of 
migratory dendritic cells arriving in the nodes (Fig. S6k), 
suggesting that lymphatic drainage of the tumor bed is simi-
lar in Cre− and Cre+ animals.
Taken together, our data reveal that lymphatic MAFB 
regulates lymphatic branching and morphogenesis during 
active developmental and pathological lymphangiogenesis, 
but is not required for the normal lymphatic architecture and 
function in healthy adult mice.
Discussion
While the initial steps leading to the embryonic development 
of the lymphatic system have been described to considerable 
extent [14], the precise signaling events and transcriptional 
programs that lead to LEC specification and differentiation 
and that control the formation and maturation of the lym-
phatic system in the growing organism are still not com-
pletely understood. VEGF-C signaling plays an important 
role in these processes, not only by guiding the sprouting 
and migration of LECs from the cardinal vein [17], but also 
by regulating the expression of PROX1 [18, 36]. Recently, 
the transcription factor HHEX was shown to be a critical 
upstream regulator of the VEGF-C/VEGFR-3 axis during 
early lymphatic development, and its absence in the vascu-
lature resulted in severe lymphatic defects during embryo-
genesis [37]. Furthermore, specific signal transduction 
events, including VEGFR-3 phosphorylation and subsequent 
induction of ERK, have been identified in the developing 
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lymphatic system [38]. However, the transcriptional events 
downstream of VEGFR-3 activation that are responsible for 
its developmental role are still largely unknown.
We and others have previously identified the transcrip-
tion factor MAFB as a direct target of VEGF-C/VEGFR-3 
signaling in LECs [9, 10]. Functionally, we found that global 
MAFB deletion in mice resulted in an early lymphatic 
patterning defect, manifesting in a hyper-branched lym-
phatic network in the skin of E14.5 embryos which in 
terms of overall vessel growth, however, appeared rela-
tively normal [10]. In line with this, zebrafish carrying a 
mutant, non-functional MAFB primarily had deficits in LEC 
migration, but not in VEGF-C induced LEC proliferation 
[9]. Of note, in both these studies, MAFB was deleted or 
Fig. 4  Lymphatic deletion of MAFB is dispensable for dermal lym-
phatic morphology and drainage capacity in healthy adult mice. a 
Schematic representation of the tamoxifen treatment schedule and 
analysis in adult mice. b Representative confocal images (maximum-
intensity projections) of split ear whole mounts of 8-week-old mice 
stained for LYVE-1 (green), CD31 (red), and PROX1 (blue). Number 
of vessel junctions normalized to total vessel length (c), number of 
vessel segments normalized to total vessel length (d), average seg-
ment length, (e) and total lymphatic vessel length (f) in the ear skin 
of  Mafbfl/fl (Cre −) and Prox1-CreERT2 ×  Mafbfl/fl (Cre +) mice (n ≥ 8 
animals/group). Scale bar: 100 μm. g Representative images showing 
clearance of an intradermally injected near-infrared lymphatic tracer 
(PEG20-IRDye800) in ears of  Mafbfl/fl (Cre −) and Prox1-CreERT2 × 
 Mafbfl/fl (Cre +) mice. h Quantification of tracer half-life in the ear 
skin (n ≥ 13 animals/group). Data represent mean ± SD. Significance 
was determined by unpaired Student’s t-test
418 Angiogenesis (2020) 23:411–423
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Fig. 5  Lymphatic MAFB deletion increases tumor-associated lym-
phangiogenesis. a Schematic representation of the treatment sched-
ule with oxazolone to induce cutaneous hypersensitivity reactions 
in the ear skin. Mice were sensitized on day −5 and challenged by 
oxazolone application to the ears on days 0 and 4. b Representative 
immunofluorescence images of ear sections from  Mafbfl/fl (Cre −) and 
Prox1-CreERT2 ×  Mafbfl/fl (Cre +) mice stained for LYVE-1 (green), 
MECA-32 (red), and Hoechst (blue). Scale bars: 100  μm. Quantifi-
cation of the lymphatic vessel number (normalized to epidermis 
length, n = 8 animals/group) (c), percentage of the LYVE-1 stained 
area (n = 8 animals/group) (d), and the number of MECA-32 + blood 
vessels (normalized to epidermis length, n = 8 animals/group) (e). f 
Schematic representation of the subcutaneous MC38 tumor model. 
g Representative immunofluorescence images of MC38 tumors from 
 Mafbfl/fl (Cre −) and Prox1-CreERT2 ×  Mafbfl/fl (Cre +) mice stained 
for LYVE-1 (green), MECA-32 (red), and Hoechst (blue). Scale bars: 
50 μm. Quantification of the lymphatic vessel number per field (n ≥ 8 
animals/group) (h), percentage of the LYVE-1 stained area (n ≥ 8 
animals/group) (i), and the number of MECA-32 + blood vessels per 
field (n ≥ 8 animals/group) (j). Data represent mean ± SD. Signifi-
cance was determined by unpaired Student’s t-test, *p < 0.05
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mutated globally. Thus, it has remained unclear whether 
MAFB intrinsically expressed by LECs is required for nor-
mal lymphatic development, or whether MAFB expressed 
by other cell types, in particular macrophages, is involved. 
To investigate these issues, we established a mouse model 
with conditional deletion of MAFB specifically in LECs. 
We chose the Prox1-CreERT2 driver mouse line as it cur-
rently is the most lymphatic-specific Cre mouse line that 
spares the myloid/macrophage compartment, in contrast to 
e.g., the LYVE-1-Cre mouse. Using this model, we show 
that LEC-specific deletion of MAFB fully recapitulates the 
embryonic lymphatic defects observed previously in global 
Mafb knockout mice, i.e., a hyper-branching of the dermal 
lymphatic network. In contrast to global MAFB deletion 
which is perinatally lethal [22], lymphatic-specific MAFB 
deletion also allowed us to study postnatal lymphatic devel-
opment in the absence of lymphatic MAFB. Interestingly, 
lymphatic hyper-branching was also evident in the capil-
lary network of the diaphragm at P7 and after pathologi-
cally induced neo-lymphangiogenesis in tumor-bearing adult 
mice. On the other hand, vessels that do not branch such 
as the mesenteric collectors and lacteals were not affected.
The lymphatic hyper-branching phenotype after global 
or tissue-specific MAFB deletion was subtle, and did not 
affect the lymphatic network morphology or the lymphatic 
transport function in healthy adult mice. Possibly, functional 
redundancy between MAFB and the other large MAF tran-
scription factors (MAFA and c-MAF) might be a reason why 
we did not observe more striking effects on the lymphatic 
system. Similarly, single MAFB deletion had only very sub-
tle effects on the differentiation of e.g., macrophages [3, 39], 
although MAFB is highly expressed in these cells. In con-
trast, double-knockout of MAFB and c-MAF clearly altered 
the proliferative potential of myeloid cells [39], suggesting 
that large MAF transcription factors can indeed compensate 
for each other, at least to some extent.
Currently, the regulation of lymphatic branching is poorly 
understood. Apart from VEGF-C, other extrinsic factors 
controlling lymphatic sprouting and branching have been 
identified, such as TGF-ß [40] and Wnt5a [41]. Further 
studies are required to investigate whether MAFB is also 
activated by any of those factors. Furthermore, the transcrip-
tional targets of MAFB that mediate its function during the 
sprouting process in LECs still need to be identified. We 
previously found that MAFB regulates several LEC differ-
entiation genes, including Prox1 and VEGFR-3, but their 
involvement in vascular branching is not fully understood. 
Possibly, incomplete or altered differentiation of LECs due 
to MAFB deletion might delay the maturation and pruning 
of the growing lymphatic network, resulting in a transient 
relative increase of network complexity with more junctions 
and vessel branches. Another potential explanation for the 
hyper-branching phenotype could be that MAFB regulates 
the cytoskeleton and cellular morphology of LECs. In this 
regard, a previous report described that MAFB deletion in 
macrophages resulted in increased formation of branched, 
cellular protrusions in response to stimulation, due to altera-
tions in the actin cytoskeleton [39]. However, we found no 
difference in the formation of filopodia in growing dermal 
lymphatic sprouts at E14.5 after MAFB deletion. Further-
more, MAFB has also been implicated in LEC migration 
in zebrafish, so it is tempting to speculate that MAFB 
may control lymphatic vascular branching by regulating 
LEC migration (and, potentially, anastomosis of nearby 
sprouts) in response to VEGF-C gradients. Interestingly, 
MAFB appears to exert a different function during blood 
vessel development, as it promoted retinal vessel sprouting 
[42]. Thus, the activation and or the transcriptional targets 
of MAFB likely differ in blood and lymphatic vessels, but 
additional studies are needed to pinpoint the molecular basis 
for these divergent roles of MAFB in different types of vas-
cular beds.
Material and methods
Cell culture, adenoviral transduction, cord 
formation, and proliferation assay
Primary human dermal microvascular LECs [43] were cul-
tured under standard culture conditions (37 °C and 5% CO2) 
on collagen-I (Advanced BioMatrix) coated dishes (50 µg/
mL) in EBM medium (Lonza) containing 20% FBS (Gibco), 
1% penicillin/streptomycin (Gibco), 2 mmol/L l-glutamine 
(Gibco), 25 µmol/mL cAMP (Sigma-Aldrich) and 10 µg/
mL hydrocortisone (Sigma-Aldrich). For overexpression of 
MAFB, ready-made adenoviral vectors (Sirion Biotech) with 
the human MAFB cDNA under control of the cytomegalo-
virus (CMV) promoter (AdMAFB) were used. A CMV:GFP 
(AdGFP) vector served as a control. For silencing of MAFB, 
a ready-made adenoviral vector (Sirion Biotech) with a pre-
validated shRNA targeting MAFB under the U6 promoter 
(AdShMAFB) and a non-targeting control shRNA construct 
(AdNT) were used. For transduction, LECs were infected 
with adenovirus at a MOI of 25 for AdGFP and AdMAFB 
or at a MOI of 50 for AdNT and AdShMAFB. Four hours 
after the infection, the medium was replaced and cells were 
subjected to a cord-like structure morphogenesis assay 
essentially as described previously [20]. In brief, LECs were 
seeded on collagen-coated 24-well plates (8 × 104/well) and 
grown to confluency. Cells were incubated for 8 h in EBM 
plus 5% FBS and subsequently overlaid with 500 µL of a 
collagen hydrogel (1 mg/mL). Endothelial cord-like struc-
tures were imaged 16 h later using an inverted microscope 
(Zeiss) and analyzed using ImageJ. RNA was isolated from 
cells cultured as monolayers or after formation of cord-like 
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structures, 72 h after adenoviral infection, using the Nucle-
ospin RNA kit (Macherey–Nagel) according to the manu-
facturer’s instructions. RNA concentrations were measured 
using a NanoDrop ND-1000 spectrophotometer (Witec), and 
retrotranscribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems).
To assess proliferation, adenovirus-transduced LECs 
were seeded in collagen-coated 96-well plates (4000/well) 
and cultured for the indicated time periods. Proliferation was 
analyzed by adding 100 µg/mL 4-methylumbelliferyl hep-
tanoate (MUH, Sigma-Aldrich) in PBS and measurement on 
a SpectraMax Reader (Molecular Devices) at 355 nm excita-
tion and 460 nm emission [44].
Mice
To create the conditional lymphatic-specific MAFB knock-
out mouse model, mice carrying a Mafb gene flanked by 
loxP elements [30] were crossed with Prox1-CreERT2 mice 
[31], kindly provided by Dr. Taija Mäkinen, Uppsala Uni-
versity, Sweden) to generate Prox1-CreERT2 × Mafbfl/fl mice 
on the C57BL/6 background. To induce embryonic deletion 
of MAFB, pregnant females were injected intraperitoneally 
at E11.5 with 50 mg/kg of tamoxifen (Sigma) dissolved in 
ethanol/sunflower seed oil. To induce postnatal gene dele-
tion, tamoxifen was administered intragastrically (50 µg per 
dose) to pups daily from P1 to P3 [32]. In another set of 
experiments, adult mice were administered tamoxifen intra-
peritoneally (50 mg/kg) for 5 consecutive days and analyzed 
3 weeks after the last injection. Prox1-CreERT2 × Mafbfl/fl 
and  Mafbfl/fl control littermates were subjected to the same 
treatment regimen and all the experiments were performed 
in a blinded fashion. All mice used in this study were bred 
and housed in an SOPF animal facility of ETH Zurich and 
experiments were performed in accordance with animal pro-
tocols approved by the local veterinary authorities (Kanton-
ales Veterinäramt Zürich).
LEC isolation and determination of recombination 
efficiency
For isolation of primary mouse endothelial cells, ears of 
Prox1-CreERT2 × Mafbfl/fl and  Mafbfl/fl tamoxifen treated 
mice were split, minced, and digested with collagenase 
IV (Life Technologies) and DNaseI (Roche) for 30 min 
at 37 °C under constant agitation. Samples were passed 
through a 40 µm cell strainer, washed twice with FACS 
buffer (PBS, 1% FBS, 2 mM EDTA), and stained with pri-
mary antibodies [rat anti-mouse-CD45 antibody conjugated 
to APC–Cy7 (BioLegend 103115, 1:200); rat anti-mouse-
CD31 antibody conjugated to APC (BD 551262, 1:300); 
hamster anti-mouse-podoplanin antibody conjugated to PE 
(eBioscience 12-5381, 1:400)] for 20 min on ice. 7AAD was 
used for discrimination of living and dead cells. Sorting of 
7AAD – CD45 – CD31 + podoplanin + singlet LECs and 
7AAD – CD45 – CD31 + podoplanin – singlet BECs was 
done using a FACS Aria II instrument (BD). DNA from 
LECs and BECs was isolated using the Nucleospin Tissue 
XS kit (Macherey–Nagel) according to the manufacturer’s 
instructions.
Quantitative polymerase chain reaction
Gene expression in human LECs as well as MAFB knockout 
efficiency in mouse LECs and BECs was measured by qPCR 
using the PowerUp SYBR green master mix (Thermo Fisher) 
on a QuantStudio 7 Flex system or an 7900 HT Fast instru-
ment (Applied Biosystems). GAPDH served as an internal 
control. Relative expression of genes was calculated accord-
ing to the  2−ΔCT formula. Primer sequences for human cells 
were: MAFB-fwd: TCA AGT TCG ACG TGA AGA AGG; 
MAFB-rev: GTT CAT CTG CTG GTA GTT GCT; GAPDH-
fwd: 5′-CAT GAG AAG TAT GAC AAC AGC-3′; GAPDH-rev: 
5′-AGT CCT TCC ACG ATA CCA AAG-3′. Primer sequences 
for isolated mouse cells were: MAFB1-fwd: TTC GAC GTG 
AAG AAG GAG CC; MAFB1-rev: GTA GTT GCT CGC CAT 
CCA GT; MAFB2-fwd: TGA GCA TGG GGC AAG AGC TG; 
MAFB2-rev: CCA TCC AGT ACA GGT CCT CG; MAFB3-
fwd: AGG GTA TGA CTG TGT GTG CT; MAFB3-rev: CAA 
GCC AGA ATG CAA AAG CG; GAPDH-fwd: CCT GGA GAA 
ACC TGC CAA GTATG; GAPDH-rev: AGA GTG GGA GTT 
GCT GTT GAA GTC .
Morphological analysis of lymphatic vessels 
in tissue whole mounts
Back skin from E14.5 embryos and diaphragms, small 
intestine and mesenteries from P7 pups or P39 adolescent 
mice were collected. Tissue wholemounts were fixed with 
paraformaldehyde (PFA), blocked in blocking solution (5% 
donkey serum, 0.2% BSA, 0.3% Triton X-100, and 0.05% 
NaN3 in PBS), and stained with primary antibodies (in 
blocking solution) O/N at 4 °C, followed by washing in PBS 
and incubation with secondary antibodies in PBS for 2 h 
at RT. Primary antibodies were: rat anti-CD31 (1:200, BD 
Biosciences, 550274), rabbit anti-LYVE-1 (1:600, Angio-
Bio, 11-034), rabbit anti-PROX1 (1:200, Angiobio, 11-002), 
goat anti-PROX1 (1:200, R&D, AF2727), goat anti-NRP2 
(1:200, R&D, AF567), rat anti-endomucin (1:200, San-
taCruz, sc-53941) and rabbit anti-MAFB (1:200, Sigma, 
HPA005653). Secondary antibodies were: donkey anti-goat 
AlexaFluor488, donkey anti-rat AlexaFluor488, donkey anti-
rabbit AlexaFluor488, donkey anti-rabbit AlexaFluor594, 
donkey anti-goat AlexaFluor594, donkey anti-rat Alex-
aFluor647, and donkey anti-rabbit AlexaFluor647 (all from 
Life Technologies). Confocal images (z-stacks) were taken 
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with an LSM780 or LSM880 microscope (Zeiss), and max-
imum-intensity projections and image analysis were done 
with ImageJ (NIH). Network parameters (number of junc-
tions, number of segments, average segment length) were 
determined after manually marking each vessel using the 
“Analyze skeleton” plugin.
Lymphangiogenesis determination in tissue 
sections
OCT-embedded tissue samples from Prox1-CreERT2 × 
 Mafbfl/fl and  Mafbfl/fl mice were frozen with liquid nitrogen, 
and 7-μm cryostat sections were prepared. After fixation 
in acetone and rehydration in 80% methanol, the sections 
were blocked (5% donkey serum, 0.2% BSA, 0.3% Triton 
X-100, and 0.05% NaN3 in PBS), followed by incubation 
with the respective primary antibodies [goat anti-mouse 
LYVE-1 (1:100, R&D, AF2125) and rat anti-mouse MECA-
32 (1:200, BD Biosciences, 553849)] O/N at 4 °C. After 
washing, sections were incubated with donkey anti-goat 
AlexaFluor488 and donkey anti-rat AlexaFluor594 sec-
ondary antibodies together with Hoechst 33342 (all from 
Life Technologies) for 1 h at room temperature. Slides were 
mounted with Mowiol mounting medium. Tissue sections 
were imaged on an Axioskop2 mot plus microscope (Zeiss) 
with an AxioCam MRc camera (Zeiss). At least 4 images 
were acquired per sample. For the ears, regions of interest 
were defined as the area of one ear half between stratum 
corneum and central cartilage. The LYVE-1 positive area 
was measured and vessels were counted using ImageJ in 
a blinded fashion. Results are expressed as positive area, 
vessel count and vessel size. For the ears, the number of 
vessels was normalized to the basement membrane length, 
as inflammatory edema causes an increase in tissue area.
Lymphatic clearance assay
The polyethylene glycol-conjugated lymphatic tracer 
PEG20-IRDye800 was prepared as described previously 
[33]. To examine lymphatic clearance over time, healthy or 
oxazolone inflamed mice (8 days after oxazolone challenge) 
were anesthetized with isoflurane, and 3 μL of 3 μM tracer 
was injected intradermally into the ear skin [45]. The mice 
were positioned in an IVIS Spectrum imaging system and 
an image was acquired just after tracer injection, with an 
exposure of 2 s (λex: 745 nm, λem: 800 nm, binning of 4), 
and then at 1 h, 2 h, 5 h and 8 h after the injection. Between 
the different imaging timepoints, mice were allowed to wake 
up and move freely. In order to calculate tissue enhancement 
values, all signal intensities were adjusted to baseline ear 
signals before tracer injection. The tissue enhancement value 
obtained directly after the injection of the tracer was used 
to normalize all values of the subsequent measurements. 
A 1-phase exponential decay model was used [45] to fit 
a decay curve for each mouse, from which the lymphatic 
clearance expressed as tracer half-life was deduced (Half-
life = ln(2/K), where ln is the natural logarithm and K is the 
decay constant).
Cutaneous hypersensitivity assay
A CHS response was induced in the ear skin of 8-week-old, 
tamoxifen treated Prox1-CreERT2 ×  Mafbfl/fl and  Mafbfl/fl 
mice as described [46]. Briefly, mice were anesthetized by 
isoflurane inhalation and sensitized by topical application 
of 2% oxazolone (4-ethoxymethylene-2 phenyl-2-oxazo-
line-5-one; Sigma) in acetone/olive oil (4:1 vol/vol) on the 
shaved abdomen (50 μL) and on each paw (5 μL). Five days 
after sensitization, 10 μL of a 1% oxazolone solution were 
applied topically to each side of the ears and again 4 days 
later. The ear thickness was measured every other day until 
the end of the experiment using a caliper. The increase in 
ear thickness over baseline levels was used to measure the 
extent of inflammation.
MC38 tumor model
Eight-week-old female Prox1-CreERT2 ×  Mafbfl/fl and 
 Mafbfl/fl mice were treated with tamoxifen (50 mg/kg) for 5 
consecutive days. Three days after the last tamoxifen injec-
tion, mice were shaved and injected with 1 × 105 MC38 cells 
(kindly provided by Dr. Tiziana Schioppa, Humanitas Clini-
cal and Research Center, Milan, Italy) in 50 µL PBS subcu-
taneously in the flank and tumors were grown for 17 days. 
Cells were routinely checked for mycoplasma contamination. 
At the endpoint, tumors were collected and embedded in 
OCT for immunofluorescent staining and inguinal and axil-
lary tumor-draining lymph nodes were collected, weighted 
and processed for flow cytometry. LNs were minced, and 
digested in LN digestion mix (0.4 mg/mL collagenase IV 
(Gibco) and 40 μg/mL DNase I (Roche) in DMEM (Gibco) 
containing 2% FCS and 1.2 mM  CaCl2 for 30 min at 37 °C. 
LN fragments were mechanically disaggregated using an 
automated multichannel pipette before the cell suspension 
was filtered through a cell strainer. Cells were incubated 
with Fc blocker (1:50, BioLegend, 101302) prior to staining 
with fluorescent antibodies for 20 min on ice. Antibodies 
used were CD45-APC-Cy7 (1:400, BioLegend, 103116), 
CD11c-PE-Cy7 (1:400, BioLegend, 117318) and MHCII-
AF700 (1:800, BioLegend, 107622). Live/dead cell staining 
with Zombie-Aqua (1:500, BioLegend, 423102) was done 
together with the antibody incubation. After washing, cells 
were resuspended in FACS buffer for acquisition using a 
Beckman Coulter CytoFLEX S flow cytometer. FACS data 
were analyzed using FlowJo version 10.5.3 software (BD 
Biosciences).
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Statistical analyses
Statistical analyses were performed using Prism ver-
sion 7.0a (GraphPad Software Inc.). Data are shown 
as mean ± SD. To determine statistical significance, a 
2-tailed, unpaired Student’s t-test (for the comparison of 
2 groups) or a 2-way ANOVA (for grouped analyses and 
repeated measures) with Bonferroni post-test were per-
formed. Differences were considered statistically signifi-
cant at p < 0.05.
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